

VOYAGE 2023

NEWSLETTER

Department of Pharmacology
GMC, Kottayam

NO.1





Department of Pharmacology, GMC, Kottayam

CONTENTS

PAGE 1

Message from Principal

PAGE 2-10

VOYAGE 2023

The various activities conducted by the Department,
and Faculty of the Department

Journey of my Soul
Good Clinical Practice
Learning Pharmacology-Movie world
Repurposed Drugs 2023
Banned Medicines in India 2023
2024 Adult Immunisation Schedule

PAGES 35-40

BRAIN TEASING CORNER

PAGE 11-34

WRITE UPS

Antimicrobial Stewardship Programme
രോഗി കേടും വൈദ്യൻ കല്പിച്ചതും
FDA Approved in 2023
Pharmacovigilance

Quiz
Crossword
Riddles

MESSAGE FROM PRINCIPAL

DEAR ALL

Drugs and chemicals are the cornerstones to medical treatment. By understanding them well and judiciously using them a doctor saves mankind .

This process of learning is difficult and needs experienced pharmacologists to facilitate this .

The Department of Pharmacology of this institution excel in this venture and now they have brought out this news letter to consolidate the work done.

I wish them all success and hope it will encourage more faculty and students to participate in this most enjoyable learning method.


Let success be sustained by your imaginative minds



Dr Sankar Sundaram
PRINCIPAL
GMC KOTTAYAM

VOYAGE 2023

WOMEN'S DAY 2023



Online release of DigitAll themed video of Women's Day by Dr Sabeena K (https://youtu.be/EmsaEzoH07A?si=-aY_awDWjD0pw20n), Quiz for Junior Residents and Zumba with a message to lead a healthy and active life



ENVIRONMENTAL DAY 2023 NATIONAL WEBINAR-ECOPHARMACOLOGY

**NATIONAL WEBINAR ON
ECOPHARMACOLOGY
JUNE 5, 2023**



DEPARTMENT OF PHARMACOLOGY,
GMC KOTTAYAM



CLICK HERE

Dear colleagues,

Pharmaceuticals are lifesaving medicines to mankind, but when their residues remain in the environment there will be a negative impact on the ecosystem which was never thought of.

As a part of Diamond Jubilee Year Faculty Development Program Series, the Department of Pharmacology, GMC Kottayam cordially invites you to the webinar on Ecopharmacology which discusses the disastrous effects of pharmaceuticals made to the ecosystem and the solutions for this pollution.

Patrons:
Dr. Sankar S, Principal, GMC Kottayam
Dr. Sabaretha K, Professor and Head of Pharmacology

Organizing Chairperson: Dr. Neethu Soman
Organizing Secretary: Dr. Hyma V

Last date of registration: June 3, 2023
Contact: 9641891541, 08950550960
pharmacologykottayam@gmail.com

Program Schedule:
10.30 am - 10.35 am
Ecopharmacology - Where do we stand now?
Dr. Haril Sankar RN
Assistant Professor, Pharmacology, GMC Kottayam


10.35 am - 10.50 am
Why did our country ban Coflutin use in humans?
Dr. Abdul Ghafar
Coordinator, Chemical Detection in AMU
Consultant in Infectious Diseases, Apollo Hospitals, Chennai

10.50 am - 11.00 am
Inaugural speech: Dr. Sankar S
Principal, GMC Kottayam

11.00 am - 11.35 am
Audit and in literature - A brief review of literature
Dr. SP-Dhanva
Professor (C-AP), Pharmacology, GMC Kottayam

11.35 am - 11.50 am
Gaps in safe disposal of medicines
Dr. Anurag T. Alosyous
Dr. Neethu Mohan
Junior residents, Pharmacology, GMC Kottayam

11.50 am - 12.00 noon
Safe disposal of medicines - Are you really aware?
Dr. Rajith Jose
Assistant Professor (C-AP), Pharmacology, GTDMC, Nagercoil



In connection with the World Environment Day celebration and college diamond jubilee year faculty development series we conducted a webinar on Ecopharmacology . Two hundred and seventy five delegates attended the webinar on google platform. Dr Neethu Mohan, JR and Dr Anurag T Alosyous, JR presented their papers on Safe Drug Disposal



NATIONAL TRAINING ON GCP, REGULATORY GUIDELINES AND GRANT WRITING IN CLINICAL RESEARCH

Contact Us

Dr. Harl Sankar KN 944660295

pharmacologykottayam@gmail.com

Golmedex Hall, 3rd Floor, C Block, GMC Kottayam

Click to Register

REGISTRATION DETAILS

Account number: 6710189077

Name: PROFESSOR AND HOD OF PHARMACOLOGY/INSTITUTIONAL REVIEW BOARD

College KOTTAYAM

IFSC Code: SBIN0070711

Registration Amount: Rs 1000 till June 12

Spot: Rs 1500

FERCI

Applied for KSMC credit hours

NATIONAL LEVEL TRAINING ON GCP, REGULATORY GUIDELINES AND GRANT WRITING IN CLINICAL RESEARCH

17 JUNE 2023

ORGANISED BY

DEPARTMENT OF PHARMACOLOGY AND INSTITUTIONAL REVIEW BOARD GMC KOTTAYAM

DIAMOND JUBILEE AND RESEARCH DAY CELEBRATIONS FACULTY DEVELOPMENT PROGRAMME

PROGRAMME SCHEDULE

08.00 - 09.00 REGISTRATION

09.00 - 10.00 WELCOME ADDRESS BY DR. ASHOK SHENOY & DR. ANIMESH JAIN

10.00 - 10.30 PRESENTATION

10.30 - 11.00 BREAK

11.00 - 11.30 LUNCH

11.30 - 12.00 PRESENTATION

12.00 - 12.30 BREAK

12.30 - 13.00 PRESENTATION

13.00 - 13.30 BREAK

13.30 - 14.00 PRESENTATION

14.00 - 14.30 BREAK

14.30 - 15.00 PRESENTATION

15.00 - 15.30 BREAK

15.30 - 16.00 PRESENTATION

16.00 - 16.30 BREAK

16.30 - 17.00 PRESENTATION

17.00 - 17.30 BREAK

17.30 - 18.00 PRESENTATION

18.00 - 18.30 BREAK

18.30 - 19.00 PRESENTATION

19.00 - 19.30 BREAK

19.30 - 20.00 PRESENTATION

20.00 - 20.30 BREAK

20.30 - 21.00 PRESENTATION

21.00 - 21.30 BREAK

21.30 - 22.00 PRESENTATION

22.00 - 22.30 BREAK

22.30 - 23.00 PRESENTATION

23.00 - 23.30 BREAK

23.30 - 24.00 PRESENTATION

24.00 - 24.30 BREAK

24.30 - 25.00 PRESENTATION

25.00 - 25.30 BREAK

25.30 - 26.00 PRESENTATION

26.00 - 26.30 BREAK

26.30 - 27.00 PRESENTATION

27.00 - 27.30 BREAK

27.30 - 28.00 PRESENTATION

28.00 - 28.30 BREAK

28.30 - 29.00 PRESENTATION

29.00 - 29.30 BREAK

29.30 - 30.00 PRESENTATION

30.00 - 30.30 BREAK

30.30 - 31.00 PRESENTATION

31.00 - 31.30 BREAK

31.30 - 32.00 PRESENTATION

32.00 - 32.30 BREAK

32.30 - 33.00 PRESENTATION

33.00 - 33.30 BREAK

33.30 - 34.00 PRESENTATION

34.00 - 34.30 BREAK

34.30 - 35.00 PRESENTATION

35.00 - 35.30 BREAK

35.30 - 36.00 PRESENTATION

36.00 - 36.30 BREAK

36.30 - 37.00 PRESENTATION

37.00 - 37.30 BREAK

37.30 - 38.00 PRESENTATION

38.00 - 38.30 BREAK

38.30 - 39.00 PRESENTATION

39.00 - 39.30 BREAK

39.30 - 40.00 PRESENTATION

40.00 - 40.30 BREAK

40.30 - 41.00 PRESENTATION

41.00 - 41.30 BREAK

41.30 - 42.00 PRESENTATION

42.00 - 42.30 BREAK

42.30 - 43.00 PRESENTATION

43.00 - 43.30 BREAK

43.30 - 44.00 PRESENTATION

44.00 - 44.30 BREAK

44.30 - 45.00 PRESENTATION

45.00 - 45.30 BREAK

45.30 - 46.00 PRESENTATION

46.00 - 46.30 BREAK

46.30 - 47.00 PRESENTATION

47.00 - 47.30 BREAK

47.30 - 48.00 PRESENTATION

48.00 - 48.30 BREAK

48.30 - 49.00 PRESENTATION

49.00 - 49.30 BREAK

49.30 - 50.00 PRESENTATION

50.00 - 50.30 BREAK

50.30 - 51.00 PRESENTATION

51.00 - 51.30 BREAK

51.30 - 52.00 PRESENTATION

52.00 - 52.30 BREAK

52.30 - 53.00 PRESENTATION

53.00 - 53.30 BREAK

53.30 - 54.00 PRESENTATION

54.00 - 54.30 BREAK

54.30 - 55.00 PRESENTATION

55.00 - 55.30 BREAK

55.30 - 56.00 PRESENTATION

56.00 - 56.30 BREAK

56.30 - 57.00 PRESENTATION

57.00 - 57.30 BREAK

57.30 - 58.00 PRESENTATION

58.00 - 58.30 BREAK

58.30 - 59.00 PRESENTATION

59.00 - 59.30 BREAK

59.30 - 60.00 PRESENTATION

60.00 - 60.30 BREAK

60.30 - 61.00 PRESENTATION

61.00 - 61.30 BREAK

61.30 - 62.00 PRESENTATION

62.00 - 62.30 BREAK

62.30 - 63.00 PRESENTATION

63.00 - 63.30 BREAK

63.30 - 64.00 PRESENTATION

64.00 - 64.30 BREAK

64.30 - 65.00 PRESENTATION

65.00 - 65.30 BREAK

65.30 - 66.00 PRESENTATION

66.00 - 66.30 BREAK

66.30 - 67.00 PRESENTATION

67.00 - 67.30 BREAK

67.30 - 68.00 PRESENTATION

68.00 - 68.30 BREAK

68.30 - 69.00 PRESENTATION

69.00 - 69.30 BREAK

69.30 - 70.00 PRESENTATION

70.00 - 70.30 BREAK

70.30 - 71.00 PRESENTATION

71.00 - 71.30 BREAK

71.30 - 72.00 PRESENTATION

72.00 - 72.30 BREAK

72.30 - 73.00 PRESENTATION

73.00 - 73.30 BREAK

73.30 - 74.00 PRESENTATION

74.00 - 74.30 BREAK

74.30 - 75.00 PRESENTATION

75.00 - 75.30 BREAK

75.30 - 76.00 PRESENTATION

76.00 - 76.30 BREAK

76.30 - 77.00 PRESENTATION

77.00 - 77.30 BREAK

77.30 - 78.00 PRESENTATION

78.00 - 78.30 BREAK

78.30 - 79.00 PRESENTATION

79.00 - 79.30 BREAK

79.30 - 80.00 PRESENTATION

80.00 - 80.30 BREAK

80.30 - 81.00 PRESENTATION

81.00 - 81.30 BREAK

81.30 - 82.00 PRESENTATION

82.00 - 82.30 BREAK

82.30 - 83.00 PRESENTATION

83.00 - 83.30 BREAK

83.30 - 84.00 PRESENTATION

84.00 - 84.30 BREAK

84.30 - 85.00 PRESENTATION

85.00 - 85.30 BREAK

85.30 - 86.00 PRESENTATION

86.00 - 86.30 BREAK

86.30 - 87.00 PRESENTATION

87.00 - 87.30 BREAK

87.30 - 88.00 PRESENTATION

88.00 - 88.30 BREAK

88.30 - 89.00 PRESENTATION

89.00 - 89.30 BREAK

89.30 - 90.00 PRESENTATION

90.00 - 90.30 BREAK

90.30 - 91.00 PRESENTATION

91.00 - 91.30 BREAK

91.30 - 92.00 PRESENTATION

92.00 - 92.30 BREAK

92.30 - 93.00 PRESENTATION

93.00 - 93.30 BREAK

93.30 - 94.00 PRESENTATION

94.00 - 94.30 BREAK

94.30 - 95.00 PRESENTATION

95.00 - 95.30 BREAK

95.30 - 96.00 PRESENTATION

96.00 - 96.30 BREAK

96.30 - 97.00 PRESENTATION

97.00 - 97.30 BREAK

97.30 - 98.00 PRESENTATION

98.00 - 98.30 BREAK

98.30 - 99.00 PRESENTATION

99.00 - 99.30 BREAK

99.30 - 100.00 PRESENTATION

100.00 - 100.30 BREAK

100.30 - 101.00 PRESENTATION

101.00 - 101.30 BREAK

101.30 - 102.00 PRESENTATION

102.00 - 102.30 BREAK

102.30 - 103.00 PRESENTATION

103.00 - 103.30 BREAK

103.30 - 104.00 PRESENTATION

104.00 - 104.30 BREAK

104.30 - 105.00 PRESENTATION

105.00 - 105.30 BREAK

105.30 - 106.00 PRESENTATION

106.00 - 106.30 BREAK

106.30 - 107.00 PRESENTATION

107.00 - 107.30 BREAK

107.30 - 108.00 PRESENTATION

108.00 - 108.30 BREAK

108.30 - 109.00 PRESENTATION

109.00 - 109.30 BREAK

109.30 - 110.00 PRESENTATION

110.00 - 110.30 BREAK

110.30 - 111.00 PRESENTATION

111.00 - 111.30 BREAK

111.30 - 112.00 PRESENTATION

112.00 - 112.30 BREAK

112.30 - 113.00 PRESENTATION

113.00 - 113.30 BREAK

113.30 - 114.00 PRESENTATION

114.00 - 114.30 BREAK

114.30 - 115.00 PRESENTATION

115.00 - 115.30 BREAK

115.30 - 116.00 PRESENTATION

116.00 - 116.30 BREAK

116.30 - 117.00 PRESENTATION

117.00 - 117.30 BREAK

117.30 - 118.00 PRESENTATION

118.00 - 118.30 BREAK

118.30 - 119.00 PRESENTATION

119.00 - 119.30 BREAK

119.30 - 120.00 PRESENTATION

120.00 - 120.30 BREAK

120.30 - 121.00 PRESENTATION

121.00 - 121.30 BREAK

121.30 - 122.00 PRESENTATION

122.00 - 122.30 BREAK

122.30 - 123.00 PRESENTATION

123.00 - 123.30 BREAK

123.30 - 124.00 PRESENTATION

124.00 - 124.30 BREAK

124.30 - 125.00 PRESENTATION

125.00 - 125.30 BREAK

125.30 - 126.00 PRESENTATION

126.00 - 126.30 BREAK

126.30 - 127.00 PRESENTATION

127.00 - 127.30 BREAK

127.30 - 128.00 PRESENTATION

128.00 - 128.30 BREAK

128.30 - 129.00 PRESENTATION

129.00 - 129.30 BREAK

129.30 - 130.00 PRESENTATION

130.00 - 130.30 BREAK

130.30 - 131.00 PRESENTATION

131.00 - 131.30 BREAK

131.30 - 132.00 PRESENTATION

132.00 - 132.30 BREAK

132.30 - 133.00 PRESENTATION

133.00 - 133.30 BREAK

133.30 - 134.00 PRESENTATION

134.00 - 134.30 BREAK

134.30 - 135.00 PRESENTATION

135.00 - 135.30 BREAK

135.30 - 136.00 PRESENTATION

136.00 - 136.30 BREAK

136.30 - 137.00 PRESENTATION

137.00 - 137.30 BREAK

137.30 - 138.00 PRESENTATION

138.00 - 138.30 BREAK

138.30 - 139.00 PRESENTATION

139.00 - 139.30 BREAK

139.30 - 140.00 PRESENTATION

140.00 - 140.30 BREAK

140.30 - 141.00 PRESENTATION

141.00 - 141.30 BREAK

141.30 - 142.00 PRESENTATION

142.00 - 142.30 BREAK

142.30 - 143.00 PRESENTATION

143.00 - 143.30 BREAK

143.30 - 144.00 PRESENTATION

144.00 - 144.30 BREAK

144.30 - 145.00 PRESENTATION

145.00 - 145.30 BREAK

145.30 - 146.00 PRESENTATION

146.00 - 146.30 BREAK

146.30 - 147.00 PRESENTATION

147.00 - 147.30 BREAK

147.30 - 148.00 PRESENTATION

148.00 - 148.30 BREAK

148.30 - 149.00 PRESENTATION

149.00 - 149.30 BREAK

149.30 - 150.00 PRESENTATION

150.00 - 150.30 BREAK

150.30 - 151.00 PRESENTATION

151.00 - 151.30 BREAK

151.30 - 152.00 PRESENTATION

152.00 - 152.30 BREAK

152.30 - 153.00 PRESENTATION

153.00 - 153.30 BREAK

153.30 - 154.00 PRESENTATION

154.00 - 154.30 BREAK

154.30 - 155.00 PRESENTATION

155.00 - 155.30 BREAK

155.30 - 156.00 PRESENTATION

156.00 - 156.30 BREAK

156.30 - 157.00 PRESENTATION

157.00 - 157.30 BREAK

157.30 - 158.00 PRESENTATION

158.00 - 158.30 BREAK

158.30 - 159.00 PRESENTATION

159.00 - 159.30 BREAK

159.30 - 160.00 PRESENTATION

160.00 - 160.30 BREAK

160.30 - 161.00 PRESENTATION

161.00 - 161.30 BREAK

161.30 - 162.00 PRESENTATION

162.00 - 162.30 BREAK

162.30 - 163.00 PRESENTATION

163.00 - 163.30 BREAK

163.30 - 164.00 PRESENTATION

164.00 - 164.30 BREAK

164.30 - 165.00 PRESENTATION

165.00 - 165.30 BREAK

165.30 - 166.00 PRESENTATION

166.00 - 166.30 BREAK

166.30 - 167.00 PRESENTATION

167.00 - 167.30 BREAK

167.30 - 168.00 PRESENTATION

168.00 - 168.30 BREAK

168.30 - 169.00 PRESENTATION

169.00 - 169.30 BREAK

169.30 - 170.00 PRESENTATION

170.00 - 170.30 BREAK

170.30 - 171.00 PRESENTATION

171.00 - 171.30 BREAK

171.30 - 172.00 PRESENTATION

172.00 - 172.30 BREAK

172.30 - 173.00 PRESENTATION

173.00 - 173.30 BREAK

173.30 - 174.00 PRESENTATION

174.00 - 174.30 BREAK

174.30 - 175.00 PRESENTATION

175.00 - 175.30 BREAK

175.30 - 176.00 PRESENTATION

176.00 - 176.30 BREAK

176.30 - 177.00 PRESENTATION

177.00 - 177.30 BREAK

177.30 - 178.00 PRESENTATION

178.00 - 178.30 BREAK

178.30 - 179.00 PRESENTATION

179.00 - 179.30 BREAK

179.30 - 180.00 PRESENTATION

180.00 - 180.30 BREAK

180.30 - 181.00 PRESENTATION

181.00 - 181.30 BREAK

181.30 - 182.00 PRESENTATION

182.00 - 182.30 BREAK

182.30 - 183.00 PRESENTATION

183.00 - 183.30 BREAK

183.30 - 184.00 PRESENTATION

184.00 - 184.30 BREAK

184.30 - 185.00 PRESENTATION

185.00 - 185.30 BREAK

185.30 - 186.00 PRESENTATION

186.00 - 186.30 BREAK

186.30 - 187.00 PRESENTATION

187.00 - 187.30 BREAK

187.30 - 188.00 PRESENTATION

188.00 - 188.30 BREAK

188.30 - 189.00 PRESENTATION

189.00 - 189.30 BREAK

189.30 - 190.00 PRESENTATION

190.00 - 190.30 BREAK

190.30 - 191.00 PRESENTATION

191.00 - 191.30 BREAK

191.30 - 192.00 PRESENTATION

192.00 - 192.30 BREAK

192.30 - 193.00 PRESENTATION

193.00 - 193.30 BREAK

193.30 - 194.00 PRESENTATION

194.00 - 194.30 BREAK

194.30 - 195.00 PRESENTATION

195.00 - 195.30 BREAK

195.30 - 196.00 PRESENTATION

196.00 - 196.30 BREAK

196.30 - 197.00 PRESENTATION

197.00 - 197.30 BREAK

197.30 - 198.00 PRESENTATION

198.00 - 198.30 BREAK

198.30 - 199.00 PRESENTATION

199.00 - 199.30 BREAK

199.30 - 200.00 PRESENTATION

200.00 - 200.30 BREAK

200.30 - 201.00 PRESENTATION

201.00 - 201.30 BREAK

201.30 - 202.00 PRESENTATION

202.00 - 202.30 BREAK

202.30 - 203.00 PRESENTATION

203.00 - 203.30 BREAK

203.30 - 204.00 PRESENTATION

204.00 - 204.30 BREAK

204.30 - 205.00 PRESENTATION

205.00 - 205.30 BREAK

205.30 - 206.00 PRESENTATION

206.00 - 206.30 BREAK

206.30 - 207.00 PRESENTATION

207.00 - 207.30 BREAK

207.30 - 208.00 PRESENTATION

208.00 - 208.30 BREAK

208.30 - 209.00 PRESENTATION

209.00 - 209.30 BREAK

209.30 - 210.00 PRESENTATION

210.00 - 210.30 BREAK

210.30 - 211.00 PRESENTATION

211.00 - 211.30 BREAK

211.30 - 212.00 PRESENTATION

212.00 - 212.30 BREAK

212.30 - 213.00 PRESENTATION

213.00 - 213.30 BREAK

213.30 - 214.00 PRESENTATION

214.00 - 214.30 BREAK

214.30 - 215.00 PRESENTATION

215.00 - 215.30 BREAK

215.30 - 216.00 PRESENTATION

216.00 - 216.30 BREAK

216.30 - 217.00 PRESENTATION

217.00 - 217.30 BREAK

217.30 - 218.00 PRESENTATION

218.00 - 218.30 BREAK

218.30 - 219.00 PRESENTATION

219.00 - 219.30 BREAK

219.30 - 220.00 PRESENTATION

220.00 - 220.30 BREAK

220.30 - 221.00 PRESENTATION

221.00 - 221.30 BREAK

221.30 - 222.00 PRESENTATION

222.00 - 222.30 BREAK

222.30 - 223.00 PRESENTATION

223.00 - 223.30 BREAK

223.30 - 224.00 PRESENTATION

224.00 - 224.30 BREAK

224.30 - 225.00 PRESENTATION

225.00 - 225.30 BREAK

225.30 - 226.00 PRESENTATION

226.00 - 226.30 BREAK

226.30 - 227.00 PRESENTATION

227.00 - 227.30 BREAK

227.30 - 228.00 PRESENTATION

228.00 - 228.30 BREAK

228.30 - 229.00 PRESENTATION

229.00 - 229.30 BREAK

229.30 - 230.00 PRESENTATION

230.00 - 230.30 BREAK

230.30 - 231.00 PRESENTATION

231.00 - 231.30 BREAK

231.30 - 232.00 PRESENTATION

232.00 - 232.30 BREAK

232.30 - 233.00 PRESENTATION

233.00 - 233.30 BREAK

233.30 - 234.00 PRESENTATION

234.00 - 234.30 BREAK

234.30 - 235.00 PRESENTATION

235.00 - 235.30 BREAK

235.30 - 236.00 PRESENTATION

236.00 - 236.30 BREAK

236.30 - 237.00 PRESENTATION

237.00 - 237.30 BREAK

237.30 - 238.00 PRESENTATION

238.00 - 238.30 BREAK

238.30 - 239.00 PRESENTATION

239.00 - 239.30 BREAK

239.30 - 240.00 PRESENTATION

240.00 - 240.30 BREAK

240.30 - 241.00 PRESENTATION

241.00 - 241.30 BREAK

241.30 - 242.00 PRESENTATION

242.00 - 242.30 BREAK

242.30 - 243.00 PRESENTATION

243.00 - 243.30 BREAK

243.30 - 244.00 PRESENTATION

244.00 - 244.30 BREAK

244.30 - 245.00 PRESENTATION

245.00 - 245.30 BREAK

245.30 - 246.00 PRESENTATION

246.00 - 246.30 BREAK

246.30 - 247.00 PRESENTATION

247.00 - 247.30 BREAK

247.30 - 248.00 PRESENTATION

248.00 - 248.30 BREAK

248.30 - 249.00 PRESENTATION

249.00 - 249.30 BREAK

249.30 - 250.00 PRESENTATION

250.00 - 250.30 BREAK

250.30 - 251.00 PRESENTATION

251.00 - 251.30 BREAK

251.30 - 252.00 PRESENTATION

252.00 - 252.30 BREAK

252.30 - 253.00 PRESENTATION

253.00 - 253.30 BREAK

253.30 - 254.00 PRESENTATION

254.00 - 254.30 BREAK

254.30 - 255.00 PRESENTATION

255.00 - 255.30 BREAK

255.30 - 256.00 PRESENTATION

256.00 - 256.30 BREAK

256.30 - 257.00 PRESENTATION

257.00 - 257.30 BREAK

257.30 - 258.00 PRESENTATION

258.00 - 258.30 BREAK

258.30 - 259.00 PRESENTATION

259.00 - 259.30 BREAK

259.30 - 260.00 PRESENTATION

260.00 - 260.30 BREAK

260.30 - 261.00 PRESENTATION

261.00 - 261.30 BREAK

261.30 - 262.00 PRESENTATION

262.00 - 262.30 BREAK

262.30 - 263.00 PRESENTATION

263.00 - 263.30 BREAK

263.30 - 264.00 PRESENTATION

264.00 - 264.30 BREAK

264.30 - 265.00 PRESENTATION

265.00 - 265.30 BREAK

265.30 - 266.00 PRESENTATION

266.00 - 266.30 BREAK

266.30 - 267.00 PRESENTATION

267.00 - 267.30 BREAK

267.30 - 268.00 PRESENTATION

268.00 - 268.30 BREAK

268.30 - 269.00 PRESENTATION

269.00 - 269.30 BREAK

269.30 - 270.00 PRESENTATION

270.00 - 270.30 BREAK

270.30 - 271.00 PRESENTATION

271.00 - 271.30 BREAK

271.30 - 272.00 PRESENTATION

272.00 - 272.30 BREAK

272.30 - 273.00 PRESENTATION

273.00 - 273.30 BREAK

273.30 - 274.00 PRESENTATION

274.00 - 274.30 BREAK

274.30 - 275.00 PRESENTATION

275.00 - 275.30 BREAK

275.30 - 276.00 PRESENTATION

276.00 - 276.30 BREAK

276.30 - 277.00 PRESENTATION

277.00 - 277.30 BREAK

277.30 - 278.00 PRESENTATION

278.00 - 278.30 BREAK

278.30 - 279.00 PRESENTATION

279.00 - 279.30 BREAK

279.30 - 280.00 PRESENTATION

280.00 - 280.30 BREAK

280.30 - 281.00 PRESENTATION

281.00 - 281.30 BREAK

281.30 - 282.00 PRESENTATION

282.00 - 282.30 BREAK

282.30 - 283.00 PRESENTATION

283.00 - 283.30 BREAK

283.30 - 284.00 PRESENTATION

284.00 - 284.30 BREAK

284.30 - 285.00 PRESENTATION

285.00 - 285.30 BREAK

285.30 - 286.00 PRESENTATION

286.00 - 286.30 BREAK

286.30 - 287.00 PRESENTATION</

ONAM CELEBRATIONS



For the Onam celebrations our department won the second prize in competition organised by KGMCTA and third prize in competition organised by Staff Welfare Forum for the athapookalam

PHARMACOVIGILANCE SENSITISATION WEEK

3RD NATIONAL PHARMACOVIGILANCE AWARENESS WEEK
17-23 SEPTEMBER 2023

17-23 SEPTEMBER 2023
FRANZ ET AL.

ADR MONITORING CENTRE, DEPARTMENT OF PHARMACOLOGY, GMC KOTTAYAM
IN ASSOCIATION WITH PHARMACOVIGILANCE PROGRAMME OF INDIA



ORGANISED BY DR SABEENA K,
PROFESSOR AND HEAD AND
COORDINATOR, AMC

**TALK ON FM 89.6
SARGAKSHETRA**

Dr Hari Sankar KN, Deputy Coordinator, AMC and Assistant Professor will deliver an interactive talk on  FM 89.6 On the Theme " Boosting Public Confidence in Pharmacovigilance" as social media awareness campaign


POSTER AND PAMPHLET DISTRIBUTION

Department of Pharmacology,
GMC Kottayam will be distributing
posters, pamphlets and Notice to
the public and patients on
18.09.2023

ONE MINUTE TO REPORT AN ADR

ADR Reel Making competition for
MBBS, BDS, BSc Nursing students and
Junior Resident. Mail to
pharmacologykottayam@gmail.com
Cash prize:
First Rs 1000, second Rs 500

CME ON MEDICATION SAFETY

Talk on Medication Safety on 21.09.2023
from 13.00- 14.00 Hrs for Faculty,
Residents and Undergraduates at
Golmedex Hall by Dr Hyma V, Assistant
Professor Pharmacology
 [Click for registration](#)

CROSSWORD SAVING COMPETITION


For MBBS students on 20.09.2023 4 to 5 PM at Demonstration Hall, Department of Pharmacology
First Prize: Rs 1000
Second Prize: Rs 750 Third Prize: Rs 500

SKIT ON THE THEME OF WEEK


"ഒരു മയുന്നൂ പഠത്ത കഥ"
written and Directed by
Dr Eva John, Junior Resident
Department of Pharmacology, GMC
Kottayam for public awareness

CLICK HERE



 **GPS Map Camera**

Arnoorkara Kerala India



Pharmacovigilance Sensitisation Week was organised under Pharmacovigilance Programme of India from 17 to 23. CME on Medication Safety was conducted with 196 participants with Dr Hyma V as resource person. Various sessions like Essay writing, Cross word solving and reel making were organised for MBBS students. Public sensitisation was through Radio FM 89.6(<https://www.youtube.com/watch?v=tuEftzw0YIM&list=LL&index=9>), Poster distribution and a short film scripted and directed by Dr Eva John "oru marunn paranje kadha"(<https://www.youtube.com/watch?v=8douOc2H5ag&list=LL&index=10>) was released.


ANTIMICROBIAL AWARENESS WEEK



A public awareness video on the use of antibiotics was released from the Department with the involvement of all faculty, residents and other staff on 17th November 2023 in connection with the World Antimicrobial Resistance Awareness Week 2023 (https://www.youtube.com/watch?v=pQdrm-z5H_o&list=LL&index=6). This video was played during the Medex Exhibition conducted in connection with Diamond Jubilee Celebrations in the Pharmacology stall.

CLICK HERE

MEDEX PHARMACOLOGY STALL



Pharmacology Stall was set up with combined effort of the staff , residents and MBBS students for MEDEX 2023. We thank Ms Shilpa 2020 batch, Mr Arjun Raj 2020 batch and Mr Kailas 2021 batch who stood with us throughout the exhibition.

CHRISTMAS CELEBRATIONS



**Christmas was celebrated with message from HOD ,Dr Sujathamadam .
Various programmes were organised and gifts were exchanged with love**

GLIMPSES OF PRESENTATION & ACADEMIC ACTIVITIES



The residents and faculty attended various CMEs, conferences, delivered talks, presented oral papers and posters. The MBBS students who performed well in projects and research activities were appreciated. Dr Aravind V secured the 4th KUHS rank in Pharmacology for the MD Pharmacology exam July 2023



DR. ARAVIND V

FOURTH RANK 🏆


MD/MS REGULAR/SUPPLEMENTARY EXAMINATION 2023

DEPARTMENT OF PHARMACOLOGY

GOVT. MEDICAL COLLEGE KOTTAYAM

ANTIMICROBIAL STEWARDSHIP PROGRAMME

Antimicrobial resistance (AMR) is a global health and development threat. WHO has declared that AMR is one of the top 10 global public health threats facing humanity. In 2020 there were 7,00,000 deaths globally due to AMR.



3. To minimise the development of AMR

Antimicrobial resistance is an emerging threat which is resulting on exhaustion of targets and emergence of super bugs!! With the emergence of new organisms and resurgence of infections that had disappeared the mankind is at a crisis as the development of newer antibiotics is sparse and expensive.

WHY DO WE NEED ASP?

Antibiotics are the only class of drugs which when use in one patient can influence its effectiveness in other patients. Drug resistance follows the drug like a faithful shadow

AMR leads to failure of antibiotic therapy, prolonged hospitalisation, escalate the treatment costs, increase mortality and put a huge burden on healthcare system.

- World Health Assembly released the Global action plan on AMR in 2015
- India released its National action plan for AMR in 2015 (5 year plan)
- In November 2018, the Indian Council of Medical Research (ICMR) released guidelines to help Indian hospitals set up Antimicrobial Stewardship Programs (AMSP)

Due to minimal release of novel agents, it is imperative to conserve the efficacy of those that we have.

WHO CONSISTS THE STEWARDSHIP TEAM

- Microbiologist
- Infectious Disease Physician
- Clinical Pharmacologist
- Epidemiologist
- Technician
- Pharmacist
- Administrator

ANTIMICROBIAL STEWARDSHIP PROGRAMME (ASP)

Coordinated interventions designed to improve & measure the appropriate use of antimicrobials, by promoting the selection of the optimal antimicrobial drug regimen, including dosing, duration of therapy & route of administration.

The term stewardship was first used in 1996, while drawing attention to urgent need of addressing the rapidly growing problems of antimicrobial resistance in hospitals

At present, most hospitals in developed countries as well as some in India have devised their own ASPs.

GOALS OF ASPS

1. To work with health care provider

The most appropriate antimicrobial agents must be administered for the right indication in the right dose, right dosage form, right route, right frequency and duration. This also includes right information to the patients and right follow up.

2. To prevent overuse, misuse or abuse of antimicrobial agents

ACTIVITIES AND TECHNIQUES OF ASPS

1. Identification of problem pathogen and clinician education

- Identify the current hospital specific problem pathogen & resistance pattern on the data of their own microbiology lab and educate the clinician.
- Focus on priority areas like Intensive Care Units, burn and trauma wards and the management of Ventilator and Community Associated Pneumonia, surgical prophylaxis etc.
- Networking and sharing of AMR data with other hospitals at regional and national level can strengthen the AMR database

2. Treatment algorithm and guideline development

- A Hospital antibiotic policy based on local antibiogram should be formed Antibiotic order form and treatment algorithm can ensure the guideline based choice of empiric antibiotic usage
- Formulate Pocket guide book with antibiotic recommendations for commonly encountered infections.

3. Preprescription intervention

- Prior authorisation of Reserve Drugs in the AWaRe classification (Access Watch Reserve). This will reduce the expenditure on costly and restricted AMAs as well as emergence of resistance against the

4. Post prescription interventions

- Review of antibiotic orders-continue/discontinue/change
- Reduce the number of prescription for one or more AMAs and total consumption of antibiotics
- De-escalation may be facilitated


5. Dose and route optimization

Based on Pharmacokinetic/Pharmacodynamic properties

- Time/ concentration dependent killing
- Bioavailability: oral versus parenteral

CONCLUSION

In the last 20 years ASP has evolved steadily, and is now a global drive. Hospitals are implementing interventions to rationalize and limit antibiotic use. Studies evaluating their impact have shown positive results. However, the large area of unrestricted antibiotic use in the community has not yet been addressed



2021 AWaRe classification

WHO access, watch, reserve, classification of antibiotics for evaluation and monitoring of use

[who.int](https://www.who.int)



“LET US ALL JOIN TOGETHER AND FIGHT AGAINST ANTIMICROBIAL RESISTANCE”

DR SUJATHA MB
PROFESSOR AND HEAD PHARMACOLOGY
MEMBER SECRETARY, IRB.GMCK
COORDINATOR, ADR MONITORING CENTRE, PVPI
MEMBER, DRUGS AND THERAPEUTICS COMMITTEE



രോഗി കേടും വൈദ്യൻ കല്പിച്ചതും

എന്റെ HOUSE സർജൻസി കാലം, ഒരു കുട്ടി അപ്പോത്തിക്കിരി ആയതിന്റെ ചെറിയ ഒരു അഹങ്കാരം ഇല്ലാതില്ല. നല്ല തിരക്കുള്ള ORTHO OP ൽ MA THOMAS SIR ന്റെ ഒപ്പമിരുന്നു സർ പറയുന്നത് വള്ളി പുള്ളി തെറ്റാതെ OP TICKET ലോട്ട് പകർത്തുന്ന തിരക്കിലാണ് ഞാൻ. പെട്ടെന്നാണ് തിക്കി തിരക്കി ബഷീർക്ക OP ലോട്ട് കടന്നു വന്നത്.

എന്റെ വീടിനടുത്തുള്ള പലചരക്കുകടയിൽ ജോലി ചെയ്യുന്ന ബഷീർക്കയെ മുൻപേ പരിചയമുണ്ട്, ആ സ്വാതന്ത്ര്യത്തിലാണ് അദ്ദേഹം ക്യൂ തെറ്റിച്ചു അകത്തു കയറിയത്.

"എന്താ ഇക്കാ, എന്ത് പറ്റി", കാരണം ആളെ കണ്ടിട്ട് കാര്യമായ വേദനയോ പ്രശ്നങ്ങളോ തോന്നുന്നില്ല.

"പറ്റിയത് എനക്കല്ലേ!", ഒരു SUSPENSE ഇട്ട് ഇക്ക നിറുത്തി.

"എന്താ ഇക്കാ, നിങ്ങള് കാര്യം പറയൂ". അടുത്ത ഊഴം കാത്ത് നിന്ന വലുമ്മച്ചിക്ക് ഇക്കയെ ഒട്ടും ഇഷ്ടപ്പെടുന്നില്ല എന്ന് അമ്മച്ചിയുടെ മുഖത്തെ ചില നവരസങ്ങളിൽ വ്യക്തമാണ്.

"മോളേ ഞമ്മളോട് ഇജ്ജാതി ശെയ്ത്തു ചെയ്യുമെന്ന് ഞമ്മളേ വിചാരിച്ചില്ല "... എന്നെ ആകാംഷയുടെ മുൾമുനയിൽ നിർത്തിക്കൊണ്ട് ഇക്ക വീണ്ടും നിർത്തി.

"കഴിഞ്ഞ ആഴ്ച തന്ന ഗുളിക തന്നെ പ്രശ്നം".

യ്യോ! ദൈവമേ ഇനി ഗുളിക മാറിപ്പോയിട്ടുണ്ടാവുമോ?, അതോ വല്ല REACTION വന്നു കാണുമോ? ഒരു നിമിഷത്തിനുള്ളിൽ എന്റെ മനസ്സിലൂടെ ഒരായിരം ചോദ്യങ്ങൾ കയറിയിറങ്ങി. ഒരാഴ്ച മുൻപാണ് ബഷീർക്ക ഈ കുട്ടി

ഡോക്ടറിന്റെ വീട്ടിൽ നടുവേദനയ്ക്ക് ചികിത്സക്ക് വന്നത്. ഞാൻ MBBS കാലത്തു പഠിച്ച 'ESSENTIAL ORTHOPAEDICS BY J MAHESWARI' എന്ന കുട്ടി ബുക്കിൽ ആ നടുവേദനക്കുള്ള പൊടിക്കൈകൾ ഒന്നുമില്ലായിരുന്നതുകൊണ്ട് പിറ്റേന്ന് തന്നെ OP യിൽ കൊണ്ടുവന്നു MA THOMAS SIR നെ കാണിച്ചു മരുന്ന് കുറിച്ചു കൊടുത്തിരുന്നു.

എന്തായാലും ആള് കലിപ്പിലല്ല, മുഖഭാവം 'ശാന്തം' ആണ് ആ ഡൈര്യത്തിൽ തന്നെ ചോദിച്ചു "എന്ത് പറ്റി മരുന്നിനു വല്ല അലർജിയും?"

"ഏയ്, ഞമ്മക്ക് അലർജി പണ്ടേ ഇല്ല ". എന്റെ ക്ഷമ നശിച്ചു തുടങ്ങി. ദേഷ്യത്തിന്റെ രസം എന്റെ മുഖത്തു വന്നോ എന്നൊരു സംശയം ഇല്ലാതില്ല.

"ഗുളിക കഴിച്ചിട്ട്, ചൊറിച്ചിലോ, ശ്വാസമുട്ടോ എന്തെങ്കിലും ഉണ്ടോ?"

"ഏയില്ല " ഒറ്റവാക്കിൽ ഇക്ക മറുപടി പറഞ്ഞു.

"ചർദി, വയറുവേദന അങ്ങനെയെന്തെങ്കിലും?"

"ഞമ്മൾ പണ്ടേ ഇംഗ്ലീഷ് മരുന്ന് കഴിക്കാറില്ല, ഇജ്ജ് എന്തെങ്കിലും അസുഖം വന്നാൽ അന്റെ പെരേടെ അടുത്തുള്ള വൈദ്യന്റെ കഷായം ആണ് കുടിക്കാറ്". മൊത്തത്തിൽ MODERN MEDICINE നോട് ഒരു പുച്ഛഭാവം ആ മുഖത്തുണ്ട്.

ഇങ്ങനെ ആരും ഇങ്ങോട്ട് ക്ഷണിച്ചില്ലല്ലോ, വൈദ്യന്റെ അടുത്ത് പൊയ്ക്കൂടായിരുന്നോ, മനസ്സിൽ ദേഷ്യം കുടിക്കൂടി വന്നു, ഒപ്പം മുഖത്തു 'രൗദ്രവും'.

അടുത്ത ചോദ്യം ചോദിക്കുന്നതിനു മുൻപ് തന്നെ അടുത്ത മറുപടി വന്നു, " ഗുളിക അല്ല കൂയപ്പം, ഗുളികേടെ കൂടെയുള്ള നിപ്പാണ്".

"നിൽപ്പോ!" ദേഷ്യം മാറി 'അത്ഭുതം' എന്റെ മുഖത്തു വിരിഞ്ഞു.

"അതേ, ഗുളിക കഴിച്ചിട്ടുള്ള ഒരു മണിക്കൂർ നിപ്പില്ലേ അതു പടച്ചോൻ പോലും പൊറുക്കില്ല!"

ബഷീർക്കന്റെ DIALOGUE തീരുന്നതിന് മുൻപ് അദ്ദേഹത്തിന്റെ ഭാര്യയുടെ DIALOGUE ഇടയ്ക്ക് കയറി വന്നു- "അനങ്ങാതെ ബായതണ്ട് പോലെ ഓന്ന് നിക്കനെ കണ്ടപ്പം ഞമ്മള് ശെരിക്കും പേടിച്ചിരിക്കണ്".

കാര്യം വിശദീകരിച്ചു കേട്ടപ്പോൾ എന്റെ മുഖത്തു ചിരിയുടെ ഒരു മാലപ്പടക്കം തന്നെ പൊട്ടി.

(പ്രശ്നം മറ്റൊന്നുമല്ല, 'വൈദ്യൻ കല്പിച്ചതും രോഗി കേട്ടതും ഒന്നല്ല രണ്ടാണ്'.

കഴിഞ്ഞ ആഴ്ച നടുവേദനയ്ക്ക് മരുന്ന് കുറിച്ചപ്പോൾ OSTEOPOROSIS അഥവാ അസ്ഥിക്ഷയത്തിനുള്ള ALENDRONATE എന്ന ഗുളികയുടെ കൂടെ കൊടുത്ത നിർദ്ദേശങ്ങളാണ് സകല പുലിവാലും ഒപ്പിച്ചത്.

DR NEETHU SOMAN
ASSISTANT PROFESSOR PHARMACOLOGY
MEMBER KUHS ACCREDITATION TEAM
LIAISON OFFICER

മേല്പറഞ്ഞ ഗുളിക കഴിച്ച ശേഷം ഉടനെ കിടക്കുകയോ കുനിയുകയോ ചെയ്താൽ മരുന്ന് തികട്ടി കയറി വന്നു നെഞ്ച് എരിയും. അതിനാൽ അദ്ദേഹത്തോട് ഗുളിക കഴിച്ചിട്ട് ഒരു മണിക്കൂർ കിടക്കുകയോ കുനിയുകയോ പാടില്ല എന്ന് നിർദ്ദേശിച്ചിരുന്നു, കഷ്ടം അല്ലാണ്ട് എന്ത് പറയാനാണ്.

ആ പാവം കേട്ടത് 'കിടക്കുകയോ, ഇരിക്കുകയോ പാടില്ല' എന്നാണ്. ഇക്ക അതിരാവിലെ ഗുളിക കഴിച്ചിട്ട് ഒറ്റ നില്പായിരുന്നു, 'കുബേരൻ' മലയാള ചലച്ചിത്രത്തിൽ ദിലീപ് അങ്ങനെ അനങ്ങാതെ നിൽക്കുന്ന ചില രസകരമായ രംഗങ്ങൾ ഉണ്ട്.

കഥ കേട്ട് അടുത്തിരുന്നവരെല്ലാം പൊട്ടിച്ചിരിച്ചു, ഒപ്പം പിന്നിൽ നിന്ന വലുത്തച്ചിയുടെ മുഖത്ത് 'ഹാസ്യം' വിടുന്നത് ഞാൻ കണ്ടു. പക്ഷേ ബഷീർക്കയുടെ മുഖത്തു ഭാവം 'കരുണം' ആയിരുന്നു.



FDA APPROVED DRUGS IN THE YEAR 2023

SL NO	BRAND NAME	GENERIC NAME	INDICATION	MOA	ADVERSE DRUG REACTIONS
1	Leqembi	Iecanemab-irmb	Alzheimer's disease	Reduction of A β plaques	Infusion related reactions, headache
2	Brenzavvy	Bexagliflozin	Type 2 diabetes	SGLT2 Inhibitors	Female genital mycotic infections, urinary tract infections
3	Jaypirca	Pirtobrutinib	Mantle cell lymphoma	BTK inhibitor	Fatigue, musculoskeletal pain, diarrhea, edema, dyspnea, pneumonia and bruising
4	Orserdu	Elecestrant	ER+/HER2-ESR1mutmBC	ER antagonist	Musculoskeletal pain, nausea, vomiting, decreased appetite, diarrhea, increased cholesterol, AST, ALT, triglycerides, haemoglobin
5	Jesduvroq	Daprodustat	Anemia due to CKD	Inhibitor of HIF-PH1-3	Hypertension, thrombotic vascular events, abdominal pain
6	Lamzedo	Velmanase alfa-tycv	Alpha-mannosidosis	Enzyme replacement	Anaphylaxis, nasopharyngitis, pyrexia, headache, arthralgia
7	Filspari	Sparsentan	Proteinuria in IgAN	ETAR and AT1 antagonist	Peripheral edema, hypotension, dizziness, hyperkalemia and anemia

SL NO	BRAND NAME	GENERIC NAME	INDICATION	MOA	ADVERSE DRUG REACTIONS
8	Skyclarys	Omaveloxolone	Friedreich's ataxia	Unclear(Nrf2 activation)	Elevated liver enzymes, headache,nausea, abdominal pain,fatigue, diarrhea, musculoskeletal pain
9	Zavzpret	Zavegepant	Acute treatment of migraine	CGRP receptor antagonist	Taste disorders,nausea, nasal discomfort, vomiting
10	Daybue	Trofinetide	Rett syndrome	Unknown	Diarrhea, vomiting
11	Zynyz	Retifanlimab-dlwr	Merkel cell carcinoma	PD-1- blocking antibody	Fatigue, musculoskeletal pain, pruritus, diarrhea, rash, pyrexia,nausea
12	Rezzayo	Rezafungin	Candidemia/ candidiasis	1,3- β -D- glucan inhibitor	Hypokalemia,pyrexia,diarrhea,anemia,vomiting,nausea,hypomagnesemia
13	Joenja	Leniolisib	Activated P13K δ syndrome	PI3K δ Inhibitor	Headache, sinusitis, atopic dermatitis
14	Qalsody	Tofersen	ALS (SOD1 mutation)	SOD1 mRNA degradation	Fatigue, arthralgia,myalgia

SL NO	BRAND NAME	GENERIC NAME	INDICATION	MOA	ADVERSE DRUG REACTIONS
15	Elfabrio	Peguinigalsidase alfa-iwxj	Fabry disease	Enzyme replacement	Nasopharyngitis, fatigue, sinusitis, pain in extremity
16	Veozah	Fezolinetant	Menopausal vasomotor symptoms	NK3 receptor antagonist	Abdominal pain, diarrhea, insomnia, hot flushes, elevated hepatic transaminases
17	Miebo	Perfluorhexyloctane	Dry eye disease	Unknown	Blurred vision
18	Epkinly	Epcoritamab-bysp	R/R DLBCL; HGBCL	CD3/CD20 Bispecific	Cytokine release syndrome, musculoskeletal pain, injection site reactions, nausea, diarrhea
19	Xacduro	Sulbactam, durlobactam	HABP/VABP caused by Acinetobacter strains	Beta lactamase inhibitors	Abnormal LFT, Diarrhea, anemia and hypokalemia
20	Paxlovid	Nirmatrelvir, ritonavir	Covid-19	SARS-CoV- 2Mproinhibit; HIV- 1protection/C YP3A Inhibitor	Dysgeusia and diarrhea
21	Posluma	Flotufolastat F18	PET of PSMA positive prostate cancer lesions	Binds to PSMA & EMITS β+(Detectable by PET)	Diarrhea, increased blood pressure, injection site pain

SL NO	BRAND NAME	GENERIC NAME	INDICATION	MOA	ADVERSE DRUG REACTIONS
22	Inpefa	Sotagliflozin	Heart failure	SGLT1/2 inhibitor	UTI, volume depletion, diarrhea and hypoglycemia
23	Columvi	Glofitamab-gxbm	R/R DLBCL; LBCL arising from FL	CD3ε/CD20 bispecific	Cytokine release syndrome, musculoskeletal pain, fatigue
24	Litfulo	Ritlecitinib	Severe alopecia areata	JAK3/TEC kinase inhibitor	Urticaria, atopic dermatitis, herpes zoster, stomatitis
25	Rystiggo	Rozanolixizumab-noli	Myasthenia gravis in AchR or MuSK mAb+adults	FcRn Blocker	Headache, pyrexia, hypersensitivity reactions
26	Ngenla	Somatrogon-ghla	Pediatric GH deficiency	GH Receptor activator	Nasopharyngitis, hypothyroidism, oropharyngeal pain
27	Beyfortus	Nirsevimab-alip	RSV lower respiratory tract disease	RSV-F directed fusion inhibitor	Injection site reactions, rashes
28	Vanflyta	Quizartinib	FLT3 ITD+AML	FLT3 Inhibitor	Hypokalemia, hypoalbuminemia, vomiting, sepsis, URTI

SL NO	BRAND NAME	GENERIC NAME	INDICATION	MOA	ADVERSE DRUG REACTIONS
29	Xdemvy	Lotilaner	Demodex blepharitis	Mite selective GABA CL- channel inhibitor	Stinging, burning
30	Zurzuvae	Zuranolone	Postpartum depression	Positive allosteric modulation of GABAA receptors	Somnolence, dizziness, diarrrhea, UTI
31	Izervay	Avacincaptad pegol	GA secondary to AMD	C5 inhibitor	Conjunctival haemorrhage,blurred vision, increased IOP,neovascular age related macular degeneration
32	Talvey	Talquetamab-tgvs	R/R multiple myeloma	GPRC5D/CD3 bispecific	Pyrexia,disguesia,nail disorder.musculoskeletal pain,rashes
33	Elrexio	Elranatamab-bcmm	R/R multiple myeloma	BCMA/CD3 bispecific	Fatigue, injection site reaction,cough,anorexia
34	Sohonos	Palovarotene	Fibrodysplasia ossificans progressive	Retinoic acid receptor agonist(RARY)	Dry skin, dry lip,pruritis. Alopecia

SL NO	BRAND NAME	GENERIC NAME	INDICATION	MOA	ADVERSE DRUG REACTIONS
35	Veopoz	Pozelimab-bbfg	CHAPLE disease	C5 inhibitor	URTI, fracture, urticaria, alopecia
36	Aphexda	Motixafortide	HSC mobilizer in patients with multiple myeloma	CXCR4 inhibitor	Injection site reactions,pain, erythema, pruritis
37	Ojjaara	Momelotinib	Myelofibrosis in adults with anemia	JAK1/JAK2/ACVR1 Inhibitor	Thrombocytopenia, hemorrhage, fatigue, dizziness, diarrhea
38	Exxua	Gepirone	Major depressive disorder	5HT1a Receptor agonists	Dizziness, nausea, insomnia, abdominal pain
39	Pombiliti	Cipaglucosidase alfa-atga	Pompe disease	Enzyme replacement	Headache,diarrhea, fatigue, nausea
40	Rivfloza	Nedosiran	Primary hyperoxaluria type 1	Hepatic LDHA reduction	Injection site reactions
41	Velsipity	Etrasimod	Ulcerative colitis	S1P receptor modulator	Headache, dizziness, elevated liver tests
42	Zilbrysq	Zilucoplan	AchR + myasthenia gravis	C5 inhibitor	Injection site reactions, upper respiratory tract infections

SL NO	BRAND NAME	GENERIC NAME	INDICATION	MOA	ADVERSE DRUG REACTIONS
43	Bimzelx	Bimekizumab	Plaque psoriasis	IL-17A/F antagonist	Upper respiratory tract infections, oral candidiasis, gastroenteritis
44	Agamree	Vamorolone	Duchenne (DMD)	Corticosteroid	Cushingoid features, psychiatric disorders, vomiting, weight gain
45	OmvoH	Mirikizumab-mrkz	Ulcerative colitis	IL-23(p19) antagonist	URTI, arthralgia
46	Loqtorzi	Toripalimab-tpzi	Nasopharyngeal carcinoma	PD-1 Blocking antibody	Fatigue, hypothyroidism, musculoskeletal pain
47	Fruzaqla	Fruquintinib	Metastatic colorectal carcinoma	VEGFR-1/2/3 inhibitor	Hypertension, palmar plantar erythrodysesthesia, proteinuria, dysphonia, abdominal pain
48	DefenCath	Taurolidine, heparin	Catheter related bloodstream infections	Antimicrobial / anticoagulant	Hemodialysis catheter malfunction, haemorrhage, thrombocytopenia, musculoskeletal chestpain

SL NO	BRAND NAME	GENERIC NAME	INDICATION	MOA	ADVERSE DRUG REACTIONS
49	Augtyro	Repotrectinib	ROS1-positive NSCLC	ROS1/TRKA/B/C inhibitor	Dizziness, dysgeusia, peripheral neuropathy, constipation, dyspnea
50	Ryzneuta	Efbemalenograstim alfa-vuxw	Febrile neutropenia	Leukocyte growth factor	Nausea, anemia, thrombocytopenia
51	Truqap	Capivasertib	HR+,HER2-Breast cancer(PIK3CA/AKT1/PTEN-mutation)	AKT1-3 inhibitor	Diarrhea, increased RBS, FBSdecreased hb, stomatitis
52	Ogsiveo	Nirogacestat	Progressive desmoid tumors	Gamma secretase inhibitor	Diarrhea, ovarian toxicity,rash,stomatitis, cough
53	Fabhalta	Iptacopan	PNH	Factor B inhibitor	Headache, nasopharyngitis, diarrhea, abdominal pain, infections
54	Filsuvez	Birch triterpenes	Epidermolysis bullosa	Unknown	Application site reactions
55	Wainua	eplontersen	Hattr(v)- PN	Degrades TTR-mRNA	Decreased vitamin A, Vomiting

DR MEGHA O RAJ
(PREVIOUS SR,GMCK)
ASSISTANT PROFESSOR PHARMACOLOGY
MES MEDICAL COLLEGE, PERINTAHLAMANNA



PHARMACOVIGILANCE

The Pharmacology Department of Government Medical College, Kottayam has been enrolled as an **AMC (ADR Monitoring Centre) for PvPI (Pharmacovigilance Programme of India)** since 2012. Since then it has been contributing for the cause of patient safety by submitting Individual Case Safety Reports (ICSRs) to PvPI through the software VigiBase.

During this time there has been tremendous progress in building the culture of reporting ADRs among the healthcare professionals in and around Kottayam District. Our AMC has received a total of 219 ICSRs from its different stakeholders in and around Kottayam District from 1st January 2023 to 31st December 2023 which has been submitted to PvPI for further evaluation. Currently there are around 877 AMCs enrolled under PvPI across India.

If there is any suspicion that an adverse event or adverse reaction has occurred, the health care professional attending to the patient, can fill up the suspected ADR form or if a patient suspects that he/she has experienced an ADR can report to the nearest ADRs Monitoring Centres (AMCs) under Pharmacovigilance Programme of India (PvPI). Please ensure to fill in atleast the mandatory fields in a suspected ADR Reporting Form which are patient initials, age at onset of reaction, reaction term(s), date of onset of reaction, suspected medication(s) & reporter information. The details of AMCs are given on the website of IPC i.e. www.ipc.gov.in Healthcare professionals can fill in the "Suspected Adverse Drug Reaction Reporting Form" by clicking this link



and Similarly Consumers can fill in the MEDICINES SIDE EFFECT REPORTING FORM (FOR CONSUMERS) by clicking the link



for downloading the adr-reporting-form-for-consumers-in-malayalam and send it to your nearest the Adverse Drug Reaction Monitoring Centre (AMC) email or whatsapp.

E-mail ID of AMC located at GMC Kottayam :

mckpharmacadr@gmail.com

·Whatsapp number of Deputy Coordinator GMC Kottayam: **7558970809**

Toll free helpline number (1800-180-3024) can also be used to directly report an ADR (All Working Days 9:00 AM to 5:30PM).

You can also report Adverse Drug Reaction through "ADR PvPI" Mobile app (android version) by it from Google play store by using the following link



The AMC organised the following events in connection with the 3rd National Pharmacovigilance Week 2023: CME on Medication Safety on 21st September 2023- A total of 196 participants which included Doctors and medical students had attended it and they were sensitised about the medication safety, errors that can occur in the hospital, the means by which we can overcome the errors, look alike sound alike drugs and the medication reconciliation process.

Essay Writing Competition on 18th, 19th and 20th September 2023- A total of 33 medical students participated in the Essay Competitions which were conducted on three topics namely 1) Medication Errors, 2) Pharmacovigilance and Public Awareness and 3) Do's and Don'ts of Adverse Drug Reactions for sensitization on pharmacovigilance.

Cross Word Solving Competition on 20th September 2023- A total of 27 medical students participated in the Crosswords Puzzle game involving words related to Pharmacovigilance, adverse reactions and drugs withdrawn from the market due to ADR.

Competition on reel making based on the theme “**ONE MINUTE TO REPORT AN ADR**”- Total of 6 entries were received. Not only the participants but also the public who viewed the reels through various platforms of social media, understood the necessary information required and the modes to report ADRs.

Public Sensitisation through Radio FM 89.6, Notice, Posters, Video - The theme of National Pharmacovigilance Programme of India was widely publicised through Radio Talk, Distribution of Pamphlets. Also the theme were translated into Malayalam, printed and widely disseminated to the public. The department also released a public awareness video on the importance of ADR reporting

As part of Medical Exhibition (Med Ex 2023) held at Government Medical College, Kottayam from 26th October to 4th December 2023, general public and school/college students were sensitized on the importance and modes for reporting ADRs.

Sensitization on reporting ADR was held for doctors and nurses of District Tuberculosis Centre, Kottayam on 2nd Decemeber 2023.

Sensitization programme on “Why to report ADR?” was conducted on 7th December 2023 as a part of Quality Status Assessment Program which was attended Doctors, Nursing officers and pharmacists of GMC Kottayam



DR JIYO CHACKO
ASSISTANT PROFESSOR PHARMACOLOGY
DEPUTY COORDINATOR
ADR MONITORING CENTRE, PVPI
GMC KOTTAYAM

JOURNEY OF MY SOUL

*I have been through a lot before
U all see me as of now. Initially,
It was a struggle to meet daily living
Then it becomes hard in times of ailments
They took the ancient myths to heal
Crushed the life of plants and their soul
Met with healing hearts around
Nobody knows how it made possible
But they determined to prove it down the era
Took the shattered pieces of wisdom from ancient tales
Evolution filled the mind with curious quests
Searched a long to extract the potential souls
One day they found me going through the gut of 4 legged
I got astonished to see that world even though smelled rancid
But I found different ways to come out of that different world to where I belong
My journey made them their stepping stone in search of healing souls.*



DR EVA JOHN
JR PHARMACOLOGY
GMCK



DR ROSE NINNYA
PREVIOUS SR, GMCK
ASSISTANT PROFESSOR,
PHARMACOLOGY
SNIMS, ALUVA

GOOD CLINICAL PRACTICE

Good clinical practice(GCP) is defined as international ethical, scientific quality standard for the design , conduct , performance , monitoring , auditing , recording , analyses & reporting clinical trial that involve participation of human subjects.

Unethical dangerous and inhumane experiments done in during the world war and the historical background of Thalidomide tragedy,led to the development of Nurmberg code and Declaration of Helsinki which gave basic structure of ethics. The 4 pillars of ethic evolved from the Belmont principles and they include Autonomy, Justice, Beneficence and Non-Maleficence.

ICH-GCP (The International Council for Harmonisation for Technical requirements for Pharmaceuticals for Human Use – Good Clinical Practice)

GCP have 14 principles and protects participants by putting forward the rights, well being and safety of the participants. In India, Indian Council of Medical Research (ICMR) introduced the first policy statement in 1980 and ethical guidelines in year 2000. The current guideline is released in 2017. The National Medical Commission(NMC) also mandates training in ethics for knowledge acquisition.

Our department along with IRB conducted a National Level Training in June 2023 on GCP, Ethical Guidelines and Grant Writing.



**DR GNANAPRAKASAM D
JR PHARMACOLOGY,
GMC KOTTAYAM**

Learning Pharmacology- Movie World

As Mohanlal sings “sumuhartama swasti swasti” and blood appears through the corners of mouth I pause the video and ask the excited Mohanlal fans which movie it was? Despite the generation gaps, even in 2024 there are some who recognize the movie as Kamaladalam. Further while I probe into the modus operandi of poisoning in the film, there are a few who recollect it as a weedicide or insecticide mixed into the cola by Vineeth and thus we step into the concept of Organophosphorous(OP) poisoning. As I tell the class it was a poor depiction of OP poisoning as how wrongly the famous actor is shown not to have SLUDGE(salivation, lacrimation, urination, defecation, gastric distress and emesis) and bleeding instead, I feel them getting interested in the topic. This is a movie clip I have been showing for past few years ever since I became interested in the concept of showing atleast one movie clip or discussing a movie related fact in each of my class.



As I proceed with the anticholinergics stressing on the uses of atropine I also show the clip of Fahad Fazil eating mushrooms with hallucinogenic effect from the movie Carbon. As I discuss the uses of atropine in mushroom poisoning I reinstate the statement that Atropine is useful for early mushroom poisoning with muscarinic symptoms but if Fahad was brought to you in the casualty after the poisoning you shouldn't be using the same in hallucinogenic type mushroom poisoning.



One of my another favourite clip is yet another scene related to poisoning. As I play the climax scene of the movie from Pranayakalam the song

ഒരു ഭവനൽ പുഴയിൽ തെളിനിരിൽ..
പുലരി തിളങ്ങി മുകും..
ഇലകളിൽ പൂക്കളിൽ എഴുതി ഞാൻ..
ഇളവെയിലായ് നിന്നെ..

we see the hero and heroine uniting in the heaven after their death. The class is on Sedative hypnotics and the question I ask is if you were the movie director what tweaks would you have made in the movie so as to give it a happy ending?



After discussing the concept of low and high therapeutic index of barbiturates and benzodiazepines it is quite interesting when the students opine that probably “barbiturates” was bad choice by the director as the main leads proceeded to respiratory depression and death which might not have happened if it were the benzodiazepines which have high therapeutic index and also a competitive antagonist Flumazenil.

Two movies I refer to while teaching the concept of anterograde amnesia are 50 first dates



and Ormayundo ee mukham....one probably inspired from the other for obvious reasons... While anterograde amnesia is one of the reason why the benzodiazepines are used as intravenous anaesthetics it is the same reason why it has been used as a rape drug as depicted in the movie starring Amala Paul "The Teacher"



With the advent of Nipah the film scene from VIRUS was used as a set induction for the antivirals ,but however the topic was subsequently handled by some other faculty.

Playing the movie scene for case based learning is well accepted in the literature.

The use of metaphors like Methylprednisolone to Chris Evans (Captain America) and Dexamethasone to Robert Downey Junior(Iron Man), the use of acronyms in learning the names of the aminoglycosides with the main lead Rocky



in KGF playing to the BGM TAN TAN TAN.....KGF TANS expanded as Kanamycin Gentamicin Framycetin Tobramycin Amikacin and Streptomycin creates learning with enjoyable moments sustaining the interest of the least interested at least for a few moments

K-Kanamycin
G-Gentamicin
F-Framycetin
T-Tobramycin
A-Amikacin
N-Netilmicin
S-Streptomycin



In the Phase 2 AETCOM session the concept of bioethics was handled as a lecture for the past 3 batches(2019-2021). The scene in which Prithviraj denies the treatment of Kalabhavan Mani's daughter based on previous grudge in "Ayalum njanum thammil", Mohanlal pretending to do surgery on Jagathi in the movie "Ulladakkom" to take out the horse he had swallowed, Dr Vijay Nambiar in the movie "Apothecary" who uses his poor patients to test drugs hiding the fact that they are in a clinical trial without their consent are discussed to bring out the concepts of Autonomy, Beneficence and Non maleficenece.



❑ Dr Vijay Nambiar uses his poor patients to test drugs on the behest of a giant pharmaceutical company, killing a few, and leaving another few to live like the dead



ഓപ്പറേഷൻ വേണ്ട...എന്നിമ മതി



While discussing antipsychotics there is no discussion without commenting the legendary Nagavalli of Manichitrathazhu and Hari of North 24th Kaatham which are evergreen in the minds of majority of the students. I remember showing the movie poster of Vidya Balan movie "Jalsa" asking them to decipher why omeprazole with a half life of 1.5 hours was given once daily. To my disappointment none of them had watched the movie and were clueless about the 'hit and run' I was referring to.



The use of trigger films, movie clips or whole length films have been used for teaching soft skills such as professionalism, communication and ethics.[1] The term "cinemeducation" was coined by Alexander et al to refer to the use of movie clips from movies and videos to educate medical students and residents about psychosocial aspects of medicine. Kadeangadi DM et al in an editorial opined that using movie clips to engage learners in discussion makes learning active and is application of constructivist (build ideas on preexisting concepts) and social learning (exposure to positive and negative role models).[2]

While a vast majority are in line with my thinking and have watched the movies a few times there are many who are clueless and doesn't know the background of the movie, especially the whole lot who were born and brought up outside Kerala as I usually refer to the Malayalam movies. Then there is this generation gap where there is a more inclination towards watching series instead of movies. I often remind myself that I need to watch more of the Grey's Anatomy or House MD types.

PS: I cannot stop this write up without mentioning Abraham Ozler in which sevoflurane an inhalational anaesthetic was used to cause loss of consciousness while attempting kidnap in contrast to the legendary Chloroform. I won't comment about the GCS ZERO mentioned in the movie though.

References

1. Alexander M, Hall MN, Pettice YJ. Cinemeducation: an innovative approach to teaching psychosocial medical care. Fam Med. 1994;26(7):430-3. PMID: 7926359.
2. Kadeangadi DM, Mudigunda SS. Cinemeducation: Using Films to Teach Medical Students. Journal of the Scientific Society 2019; 46(3):73-4
DOI: 10.4103/jss.JSS_1_20



DR S P DHANYA
ASSOCIATE PROFESSOR/PROFESSOR (CAP)
 ASSISTANT NODAL OFFICER, MRU
 MEMBER, NMC NODAL CENTRE FOR FACULTY DEVELOPMENT
 MEMBER, KUHS ACCREDITATION COMMITTEE
PHARMACOLOGY,
GMC KOTTAYAM

REPURPOSED DRUGS -2023

"Creativity is making masterpiece out of the discarded "

Drug repurposing is a promising field in drug discovery that identifies new therapeutic indications for existing /failed /abandoned drugs. This novel approach has advantage over traditional drug discovery in mitigating high monetary cost, longer duration of development and increased risk of failure.

PDE5 INHIBITORS

Previously used for erectile dysfunction

New indication: SARS -Co-V-2 infection(anti inflammatory ,antioxidant ,immunomodulatory effects)

TERIFLUNOMIDE & FLUCONAZOLE

Synergistic effect in resistant *Candida albicans* .

Reduces fungal burden & tissue damage in comparison to monotherapy .

MILTEFOSINE

Previous indication : Leishmaniasis.

New indication : Antifungal activity against *Mucorales* species

ARTEMESININ

Previous indication : Treatment of Malaria

New indication : COVID -19 (anti inflammatory -inhibition of IL-6)



DR SRUTHI CL
JR PHARMACOLOGY,
GMC KOTTAYAM

BANNED MEDICINES IN INDIA 2023

In India, the Central Drugs Standard Control Organization (CDSCO) is responsible for ensuring the safety and efficacy of medicines. It also maintains a list of banned medicines that are no longer allowed to be manufactured, sold, or used in the country. To safeguard public health and ensure the safety and efficacy of medications, the Indian government periodically bans certain drugs. This article provides a comprehensive guide to the list of banned medicines in India as of 2023, with a focus on clarity and accessibility for the public.

Types of Banned Medicines:

There are two main categories of banned medicines in India

1. **Single Drugs:** These are individual medications that are prohibited for use due to safety concerns or lack of therapeutic justification.
2. **Fixed-Dose Combinations (FDCs):** These are medicines containing two or more drugs combined in fixed proportions. They are banned if they are found to be irrational, unsafe, or lacking proper scientific evidence to support their use.

List of Banned Single Drugs:

Amidopyrine
Phenacetin
Nialamide
Chloramphenicol (Except for ophthalmic and topical preparations)
Phenylpropanolamine
Furazolidone
Oxyphenbutazone
Metronidazole (topical application for acne)

List of Banned FDCs:

As of December 2023, a total of 14 FDCs have been banned in

India. These include:

1. Nimesulide + Paracetamol Dispersible Tablet
2. Amoxicillin + Bromhexine
3. Pholcodine + Promethazine
4. Chlorpheniramine Maleate + Phenylephrine Hydrochloride + Caffeine
5. Dextromethorphan Hydrobromide + Chlorpheniramine Maleate + Phenylephrine Hydrochloride
6. Ambroxol Hydrochloride + Guaiphenesin + Levosalbutamol + Menthol
7. Dextromethorphan Hydrobromide + Ambroxol Hydrochloride + Guaiphenesin
8. Diphenhydramine Hydrochloride + Phenylephrine Hydrochloride + Ammonium Chloride
9. Dextromethorphan Hydrobromide + Phenylephrine Hydrochloride + Chlorpheniramine Maleate
10. Dextromethorphan Hydrobromide + Doxylamine Succinate + Phenylephrine Hydrochloride
11. Pholcodine + Dextromethorphan Hydrobromide + Chlorpheniramine Maleate
12. Ambroxol Hydrochloride + Dextromethorphan Hydrobromide + Guaiphenesin
13. Dextromethorphan Hydrobromide + Doxylamine Succinate + Guaifenesin
14. Dextromethorphan Hydrobromide + Chlorpheniramine Maleate + Guaifenesin



DR ABEY ABRAHAM JOY
JR PHARMACOLOGY,
GMC KOTTAYAM

Brief Summary of Updates Adult Immunization Schedule 2024

Addition of Section 5 in Schedule (Addendum)

- Affordable Care Act-compliant insurance plans ACIP recommended immunizations

New vaccines added

- Respiratory syncytial virus (RSV) vaccines**
- Pregnant at 32 weeks - 36 weeks and 6 days gestation from September to January in most of the continental United States***: 1 dose RSV vaccine (Abrysvo™). Administer RSV vaccine regardless of previous RSV infection
- mpox vaccine (Jynneos)**
Any person at risk for Mpox infection: 2-dose series, 28 days apart
- MenACWY-MenB combo vaccine (Penbraya)**

Adults may receive a single dose of Penbraya as an alternative to separate administration of MenACWY and MenB

Vaccine	Abbreviation(s)	Trade name(s)
COVID-19 vaccine	1vCOV-mRNA	Comirnaty®/Pfizer-BioNTech COVID-19 Vaccine Spikevax®/Moderna COVID-19 Vaccine
	1vCOV-aPS	Novavax COVID-19 Vaccine
<i>Haemophilus influenzae</i> type b vaccine	Hib	ActHIB® Hiberix® PedvaxHIB®
Hepatitis A vaccine	HepA	Havrix® Vaqta®
Hepatitis A and hepatitis B vaccine	HepA-HepB	Twinrix®
Hepatitis B vaccine	HepB	Engerix-B® Hepisav-B® PreHevbrio® Recombivax HB®
Human papillomavirus vaccine	HPV	Gardasil 9®
Influenza vaccine (inactivated)	IIV4	Many brands
Influenza vaccine (live, attenuated)	LAIV4	FluMist® Quadrivalent
Influenza vaccine (recombinant)	RIV4	Flublok® Quadrivalent
Measles, mumps, and rubella vaccine	MMR	M-M-R II® Priorix®
Meningococcal serogroups A, C, W, Y vaccine	MenACWY-CRM	Menveo®
	MenACWY-TT	MenQuadfi®
Meningococcal serogroup B vaccine	MenB-4C MenB-FHbp	Bexsero® Trumenba®
Meningococcal serogroup A, B, C, W, Y vaccine	MenACWY-TT/ MenB-FHbp	Penbraya™
Mpox vaccine	Mpox	Jynneos®
Pneumococcal conjugate vaccine	PCV15	Vaxneuvance™
	PCV20	Prenar 20™
Pneumococcal polysaccharide vaccine	PPSV23	Pneumovax 23®
Poliovirus vaccine	IPV	Ipol®
Respiratory syncytial virus vaccine	RSV	Arexvy® Abrysvo™
Tetanus and diphtheria toxoids	Td	Tenivac® Tdvax™
	Tdap	Adacel® Boostrix®
Tetanus and diphtheria toxoids and acellular pertussis vaccine		
Varicella vaccine	VAR	Varivax®
Zoster vaccine, recombinant	RZV	Shingrix

Colour codes

Brown to highlight those groups and conditions which need recurrent vaccination

- Tdap in each and every pregnancy at 27-36 weeks
- Revaccinate people with HIV with MenACWY every 5 years
- Revaccinate those with asplenia/complement deficiency with MenACWY every 5 years and MenB every 2-3 years
- Stem cell transplant recipients need 3 doses of Hib

- COVID and flu vaccines are placed at top and coded yellow
- These vaccinations should be provided to everyone who needs a dose of both vaccines

UPDATES

COVID vaccine (both mRNA and protein-based adjuvanted versions)

- **Unvaccinated:** - 1 dose of updated Moderna or Pfizer-BioNTech vaccine - 2-dose series of updated (2023–2024 Formula) Novavax at 0, 3–8 weeks
- **Previously vaccinated :** 1 dose of any updated COVID-19 vaccine at least 8 weeks after the most recent COVID-19 vaccine dose.

Vaccine information statements

Complete ACIP recommendations

CDC's General best practice guidelines for immunizations

VAERS(CDC's Vaccine Adverse Event Reporting System)

Travel vaccination requirements

Best practices guidelines for vaccinating persons with immunodeficiency

Travel vaccine requirements

Countries with high or intermediate endemic hepatitis A

Hep A – Hep B [Twinrix] 3 doses at 0, 7, and 21–30 days, followed by a booster dose at 12 months

Close, personal contact with international adoptee should get **HepA-HepB** in first 60 days after arrival administer dose 1 as soon as adoption is planned, at least 2 weeks before adoptee's arrival

Students in postsecondary educational institutions, international travellers should get 2-dose series at least 4 weeks apart if previously did not receive any doses of MMR or 1 dose if previously received 1 dose **MMR**

Countries with hyperendemic or epidemic meningococcal disease, or microbiologists routinely exposed to Neisseria meningitidis: 1 dose **MenACWY (Menveo or MenQuadfi)** and revaccinate every 5 years if risk remains.

NOTES

For vaccination recommendations for persons ages 18 years or younger, see the Recommended Child and Adolescent Immunization Schedule, 2024: www.cdc.gov/vaccines/schedules/hcp/child-adolescent.html



How to use the adult immunization schedule

- 1** Determine recommended vaccinations by age (**Table 1**)
- 2** Assess need for additional recommended vaccinations by medical condition or other indication (**Table 2**)
- 3** Review vaccine types, dosing frequencies and intervals, and considerations for special situations (**Notes**)
- 4** Review contraindications and precautions for vaccine types (**Appendix**)
- 5** Review new or updated ACIP guidance (**Addendum**)

Table 1 Recommended Adult Immunization Schedule by Age Group, United States, 2024

Vaccine	19–26 years	27–49 years	50–64 years	≥65 years
COVID-19	1 or more doses of updated (2023–2024 Formula) vaccine (See Notes)			
Influenza inactivated (IIV4) or Influenza recombinant (RIV4)	1 dose annually			
Influenza live, attenuated (LAIV4)	1 dose annually			
Respiratory Syncytial Virus (RSV)	Seasonal administration during pregnancy. See Notes.			≥60 years
Tetanus, diphtheria, pertussis (Tdap or Td)	1 dose Tdap each pregnancy; 1 dose Td/Tdap for wound management (see notes)			
Measles, mumps, rubella (MMR)	1 dose Tdap, then Td or Tdap booster every 10 years			For healthcare personnel, see notes
Varicella (VAR)	2 doses (if born in 1980 or later)			2 doses
Zoster recombinant (RZV)	2 doses for immunocompromising conditions (see notes)			2 doses
Human papillomavirus (HPV)	2 or 3 doses depending on age at initial vaccination or condition	27 through 45 years		
Pneumococcal (PCV15, PCV20, PPSV23)				See Notes
Hepatitis A (HepA)	2, 3, or 4 doses depending on vaccine			
Hepatitis B (HepB)	2, 3, or 4 doses depending on vaccine or condition			
Meningococcal A, C, W, Y (MenACWY)	1 or 2 doses depending on indication, see notes for booster recommendations			
Meningococcal B (MenB)	19 through 23 years	2 or 3 doses depending on vaccine and indication, see notes for booster recommendations		
Haemophilus influenzae type b (Hib)	1 or 3 doses depending on indication			
Mpox				

Recommended vaccination for adults who meet age requirement, lack documentation of vaccination, or lack evidence of immunity

Recommended vaccination for adults with an additional risk factor or another indication

Recommended vaccination based on shared clinical decision-making

No recommendation/Not applicable

Table 2 Recommended Adult Immunization Schedule by Medical Condition or Other Indication, United States, 2024

Always use this table in conjunction with Table 1 and the Notes that follow. Medical conditions or indications are often not mutually exclusive. If multiple medical conditions or indications are present, refer to guidance in all relevant columns. See Notes for medical conditions or indications not listed.

Vaccine	Pregnancy	Immunocompromised (excluding HIV infection)	HIV infection CD4 percentage and count	Men who have sex with men	Asplenia, complement deficiency	Heart or lung disease	Kidney failure, End-stage renal disease or on dialysis	Chronic liver disease, alcoholism	Diabetes	Healthcare Personnel
COVID-19		See Notes								
IIV4 or RIV4										
LAIV4				1 dose annually if age 19–49 years				1 dose annually if age 19–49 years		
RSV	Seasonal administration. See Notes.	See Notes					See Notes			
Tdap or Td	Tdap: 1 dose each pregnancy			1 dose Tdap, then Td or Tdap booster every 10 years						
MMR										
VAR			See Notes							
RZV		See Notes								
HPV		3 dose series if indicated								
Pneumococcal										
HepA										
HepB	See Notes								Age ≥60 years	
MenACWY										
MenB										
Hib		HSCT: 3 doses*			Asplenia: 1 dose					
Mpox	See Notes			See Notes						See Notes

Recommended for all adults who lack documentation of vaccination, OR lack evidence of immunity

Not recommended for all adults, but recommended for some adults based on either age OR increased

Recommended based on shared clinical decision-making

Recommended for all adults, and additional doses may be necessary based on medical condition or other indications.

Precaution: Might be indicated if benefit of protection outweighs risk of adverse reaction

Contraindicated or not recommended. *Vaccinate after pregnancy, if indicated.

No Guidance/Not Applicable



DR NEETHU MOHAN
JR PHARMACOLOGY,
GMC KOTTAYAM



Q1) A 25 year old female presented with diplopia, facial weakness, blurring of vision, numbness and weakness of both lower extremities and bladder dysfunction. MRI findings revealed



The S1P5-selective S1P inhibitor that is used in the management of relapsing form of this condition is

- a) Glatiramer acetate**
- b) Palovarotene**
- c) Ponesimod**
- d) Lumateperone**

Q2) What is the classical adverse effect seen with multikinase inhibitor- Cabozantinib?

- A) Nystagmus.**
- B) Tendinitis**
- C) Hypoglycemia**
- D) Hypertension.**

Q3) Blinatumomab is approved for the management of

- A) Rhabdomyosarcoma**
- B) Previously untreated patients with CLL in combination with chlorambucil.**
- C) Treatment-refractory or relapsed B-cell precursor acute lymphoblastic leukemia**
- D) Breast carcinoma.**

**Q4) The following skin conditions are commonly associated with the intake of certain drugs.
Match the best possible causative drug**



Image- (1)



Image (2)



Image – (3)



Image – (4)

**a) Hydralazine
c) Amantadine**

**b) Bromocriptine
d) Carbamazepine**

- Option A) 1 – d, 2- a, 3- b, 4-c**
Option B) 1- a, 2- c, 3-b, 4-d
Option C) 1- b, 2- c, 3-d, 4- a
Option D) 1 – b, 2-d, 3-c, 4-a

Q5) Pleuromutilins are effective against

- A) Enterobacter**
- B) Klebsiella**
- C) MRSA**
- D) Enterococci.**

Q6) Choose the correct statement in relation to alcohol intoxication

- A) Acute ethanol intoxication decreases general anesthetic requirements**
- B) Since ethanol is a substrate for CYP2E1, any drug being metabolized by this CYP isozyme will be metabolized at a faster rate in the presence of ethanol**
- C) Chronic ethanol drinking decreases anesthetic requirements largely due to pharmacodynamic cross-tolerance**
- D) Ethanol decreases the risk of internal bleeding associated with aspirin.**

Q7) Which of the following anti trypanosomal drug is effective when central nervous system involvement is there?

- A) Trimelarsan**
- B) Melarsoprol**
- C) Suramin**
- D) Pentamidine**

Q8) Which of the following best describes the management of Herpes Zoster ?

- A) For uncomplicated herpes zoster, valacyclovir or famciclovir is not preferable to acyclovir**
- B) Therapy should start within the first 5 days of the onset of the lesions and be continued for 14 days**
- C)Corticosteroids does not prevent the development of postherpetic neuralgia .**
- D) VZV associated with the Ramsay Hunt syndrome is more sensitive to antiviral therapy**

Q9) The preferred ocular route of drug administration in the management of Age related macular degeneration is

- A) Sub-Tenon's**
- B) Subconjunctival**
- C) Intracameral**
- D) Intravitreal injection**

Q10) Teduglutide is used in the management of

- A) Short-Bowel Syndrome**
- B) Postoperative ileus**
- C) Post gastrectomy dumping syndrome**
- D) Small Intestinal Bacterial Overgrowth(SIBO)**

ANSWERS

Q1-C Ponesimod (Ref – Harrison 21st edition – 3471)

Q2-D Hypertension(Ref- Goodman & Gilman 14th edition page-1399)

Q3-C Treatment-refractory or relapsed B-cell precursor acute lymphoblastic leukemia (ALL) (Ref- Katzung Basic & Clinical Pharmacology 15th edition page- 1477)

Q4 -C 1 - Erythromelalgia- Bromocriptine

2- Livedo reticularis-Amantadine 3-SJS-Carbamazepine

4-Lupus erythematosus- Hydralazine

Q5- C MRSA(Ref - Goodman & Gilman 14th edition page- 1187)

Q6 – A Acute ethanol intoxication decreases general anesthetic requirements(Ref- Goodman & Gilman 14th edition page- 526)

Q7- B Melarsoprol (Ref- A Textbook of Clinical Pharmacology and Therapeutics – James M Ritter , 5th edition , page – 364)

Q8- C Corticosteroids does not prevent the development of postherpetic neuralgia(Ref- CMDT 2023 page 1361)


Q9- D Intravitreal injection (Ref - Goodman & Gilman – 14th edition 1457)

Q10-A Short-Bowel Syndrome(Ref - Goodman & Gilman – 14th edition 1105)



**DR ARAVIND V
SR PHARMACOLOGY,
GMC KOTTAYAM**

Crossword



Across

2. Drug of Choice (DOC) for prevention of Acute Mountain Sickness
4. DOC for Paroxysmal Supraventricular Tachycardia
5. DOC for Graves' disease
8. DOC for coccidioidal meningitis
9. DOC for chronic hepatitis B in pregnancy
10. DOC for treatment or postexposure prophylaxis of pertussis

Down

1. DOC for tinea capitis
3. DOC for Pneumocystis jirovecii pneumonia
6. DOC for patients with phytosterolemia
7. DOC for Juvenile Myoclonic Epilepsy

KEY CLUES

2. EDIMALOZATECA
5. ELOZAMIHTEM
9. RIVOFONET
1. NIVLUFOESIRG
6. EBIMITEZE

4. ENISONEDA
8. ELOZANOCULF
10. NICYMORHTYRE
3. ELOZAXOMIRTOC
7. ETAORPLAV

**DR ANURAG T ALOSIOUS
JR PHARMACOLOGY,
GMC KOTTAYAM**

RIDDLES

1] I'm an extensively used analgesic.

My ancestor has been withdrawn from the market due to the occurrence of analgesic abuse nephropathy.

Unlike other commonly used analgesics, I have negligible anti-inflammatory effect with unique action.

In higher doses, I'm hepatotoxic and chronic alcoholics should handle me with caution.

My toxic metabolite can get neutralized by the usage of a mucolytic agent.

Guess who am I?

2] I had been extensively used in a common hyper- responsive respiratory condition.

I'm derived from Tea leaves and structurally similar to Caffeine.

I have a narrow safety margin and more prone to cause convulsions and cardiac arrhythmias.

I serve as a bronchodilator.

Guess who am I?

3] My existence has been described by the emergence of a hemorrhagic disease in cattle fed with spoiled sweet clover hay, in 1924.

Initially, I was used as a rat poison.

My action is closely associated with a fat- soluble vitamin in the human body.

I'm teratogenic in nature.

I'm active orally and has been used for prophylaxis and treatment of several thrombotic conditions.

Guess who am I?

4] I've been derived from a bacteria and act against Fungal and Protozoal infections.

Due to my severe Nephrotoxic nature, my systemic use is restricted and being used topically and via targeted delivery.

I can act by creating micropores on the target cell membrane.

Nowadays I've been prescribed for severe and refractory infections.

Guess who am I?

5] I'm a colorless, odorless and non- inflammable gas. Even though I'm a less potent anesthetic, I have a major role in General anesthesia due to my unique properties.

I'm a good analgesic and have been used for dental and obstetric analgesia.

Guess who am I?

6] I belong to the antibiotic class obtained from soil actinomycetes.

I can act by impairing bacterial protein synthesis and has broad spectrum of action.

My use is restricted in pregnancy and in children due to defective bone and teeth development.

Be cautious about sunlight exposure due to the risk of phototoxicity.

I'm the drug of choice for the Rickettsial and Chlamydial infections.

Guess who am I?

7] I'm an anticancer drug with cell cycle- synthetic phase- specific activity.

I have chemotherapeutic effect against Choriocarcinoma and Acute Lymphoblastic Leukemia.

I'm an immunosuppressive agent as well and commonly used in Rheumatoid Arthritis and Psoriasis.

My major adverse effect is Megaloblastic anemia and can be ameliorated by using rescue Folinic acid.


Guess who am I?

Answer Clues

1.lomatecaraP 2. enillyhpoehT 3. nirafraW

4. B-niciretohpMA 5. edixo suortiN

6. enilcyxoD 7.etaxertohteM



DR CHRISTY GEORGE T
SR PHARMACOLOGY,
GMC KOTTAYAM

Just like DAVID
defeated GOLIATH
Doctors can defeat
4 Prevent SUPERBUG
by proper use
of ANTIBIOTICS

ANTIBIOTICS



DOCTOR



Dr. Rose Ninnya